<i>a</i>						_			
FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE				APPLICATION NO.: 10/024,607			ATTY. DOCKET NO.: B0801.70231US00		
				FILING DATE: November 8, 2001		CONFIRMATION NO.: 6830			
	TATENT	DV ADD	LUSURE	APPLICA	ANT:	Richard T. Lee	·		
Sheet 1 3				GROUP	GROUP ART UNIT: 1646 EXAMINER: Hissong, B. D.				g, B. D.
	Cite-	9 2007		1			<u> </u>		
	Te.			U.S. I	PATENT	DOCUMENTS			·
Examiner's	Cite	U.S. Patent Document			Name of Patentee or Applicant of Cited		Date of Publication or Issue		
minais	No.	Number		Kind Code	Document		of Cited Document MM-DD-YYYY		
/BH/	A8	5,786,163	<u> </u>			Christian Hall		07-28-1998	
				FORFIC	N DATER	UT DOCUMENTS			
		Fore	eign Patent Docu		FOREIGN PATENT DOCUMENTS			Date of	
Examiner's Initials #	Cite No.	Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document MM-DD-YYYY		Translation (Y/N)		
/BH/	B7	wo	00/35951	Al		The University of Leic	ester	06-22-2000	
\/	B8	WO	99/34217	Al				07-08-1999	
V	B9	WO	98/07754	Al	World I	ntellect		02-1998	
	-							·····	
•	l		OTHER	DT NON	DATENT	LITED ATURE DOOL	MENTS	<u> </u>	L
Examiner's	Cite	Include n	ame of the autho	r (in CAPITA	AL LETTE	RS), title of the article (v	vhen appropriate	e), title of the item	Translation
Initials ** No (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published.					(Y/N)				
/BH/	C78					synthase inhibitors atte in vitro. Am J Pathol.			
	C79	factor-beta 1-stimulated capillary organization in vitro. Am J Pathol. 1997 May;150(5):1835-44. CARTER RW, et al. Regulation of ST2L expression on T helper (Th) type 2 cells. Eur J Immunol. 2001 Oct;31(10):2979-85 ABSTRACT ONLY							
	C80						lective marker	s for the	
		CHAN WL, et al. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol. 2001 Aug 1;167(3):1238-44 ABSTRACT ONLY							
	C81	OHKI R et al. Identification of mechanically induced genes in human monocytic cells by DNA microarrays. J. Hypertens., 2002 Apr; 20(4):685-691 ABSTRACT ONLY							
	C82								
	C83	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~							
		4 GenBank Submission; NIH/NCBI; Accession No. U04317 (printed 8/23/2000) (2 pages)							
W:		C85 GenBank Submission; NIH/NCBI; Accession No. E08652 (printed 8/23/2000) (2 pages) C86 NCBI BLASTN 2.2.2 [Dec-14-2001], BLAST Results (21 pages)							
	C86	MCRI RF	ASIN 2.2.2 [D	ec-14-2001	J, BLAST	Results (21 pages)			
EXAMINER: /Bruce Hissong/					DATE CONSIDERED: 12/14/2007				

EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. nelude copy of this form with next communication to Applicant.

'a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier illing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is elied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.:	10/024,607	ATTY. DOCKET N	O.: B0801.70231US00		
		FILING DATE: November 8, 2001		CONFIRMATION NO.: 6830			
		APPLICANT:	Richard T. Lee				
Sheet	2	l of l	2	GROUP ART UNIT:	1646	EXAMINER:	Hissong, B. D.

NP F	C87	NCBI BLASTN 2.2.2 [Dec-14-2001], BLAST Results (15 pages)	
/BH/	70 C88	NCBI BLASTN 2.0.14 [Jun-29-2000], BLAST Results, Query 2065 letters, (5 pages) printed August 23, 2000	
00109	INIII C39	1	
PARE PADE	C90	2000	
	C91	NCBI BLASTN 2.0.14 [Jun-29-2000], BLAST Results, 2586 letters, (5 pages) printed August 23, 2000	
	C92	Monoclonal Antibody: Anti-Human ST2; Medical & Biological Laboratories Co., Ltd., Aug. 23, 2000 (2 pages)	
	C93	Millenium Pharmaceuticals, Inc. Millenium Pharmaceuticals Identifies a Key mediator of Allergic Immune Response. Press Release October 4, 1999, 2 pages	
	C94	TANG Z, et al. Gene Expression profiling during the transition to failure in TNF-α over-expressing mice demonstrates the development of autoimmune myocarditis. Journal of Molecular and Cellular Cardiology 2004; 36:515-30	
•	C95	NAKANO M, et al. Elevation of Soluble Thrombomodulin Antigen Levels in the Serum and Urine of Streptozotocin-Induced Diabetes Model Rats. Thrombosis Research 2000; 99:83-91	
	C96	HANYU T, et al. Urinary Thrombomodulin in Patients with Rheumatoid Arthritis: Relationship to Disease Subset. 1999; 18:385-9	
	C97	NAKANO M, et al. Characterization of Soluble Thrombomodulin Fragments in Human Urine. Thromb. Haemost. 1998; 79(2):331-337	
	C98	SIMS JE, IL-1 and IL-18 Receptors, and Their Extended Family. Current Opinion in Immunology. 2002; 14:117-122	
	C99	OSHIKAWA, K, et al. Elevated Soluble ST2 Protein Levels in Sera of Patients with Asthma with an Acute Exacerbation. Am. J. Respir. Crit. Care Med. 2001; 164:277-81	
	C100	KUROIWA K, et al., Identification of Human ST2 Protein in the Sera of Patients with Autoimmune Diseases. Biochemical and Biophysical Research Communications 2001; 284:1104-8.	
$\overline{\mathbf{V}}$	C101	ONDA H, et al. Identification of Genes Differentially Expressed in Canine Vasospastic Cerebral Arteries After Subarachnoid Hemorrhage. Journal of Cerebral Blood Flow & Metabolism 1999; 19:1279-1288	

EXAMINER:	DATE CONSIDERED:
/Bruce Hissong/	12/14/2007

EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered, nelude copy of this form with next communication to Applicant.

'a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier illing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, re included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is elied upon for an earlier filing date under 35 U.S.C. §120.]

FORM PTO-1449/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICATION NO.: 10/024,607

ATTY. DOCKET NO.: B0801.70231US00

FILING DATE: November 8, CONFIRMATION NO.: 6830

APPLICANT: Richard T. Lee

1646

EXAMINER:

Hissong, B. D.

GROUP ART UNIT:

of

3

00	CT 0 9 2007	•	
BA	CIRC	WEINBERG EO, et al. Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction Circulation 2002; 106:2961-6; published online November 11, 2002	
	C103	GenBank Submission; NIH/NCBI; Accession No. AL117622 (printed 9/25/2007) (2 pages)	
	C104	GenBank Submission; NIH/NCBI; Accession No. AB022176 (printed 9/25/2007) (2 pages)	
	C105	GenBank Submission; NIH/NCBI; Accession No. AB024518 (printed 9/25/2007) (2 pages)	
	C106	GenBank Submission; NIH/NCBI; Accession No. X60184 (printed 9/25/2007) (5 pages)	
	C107	GenBank Submission; NIH/NCBI; Accession No. E07714 (printed 9/25/2007) (2 pages)	
	/ C108	GenBank Submission; NIH/NCBI; Accession No. E07716 (printed 10/18/2005) (2 pages)	
	C109	GenBank Submission; NIH/NCBI; Accession No. D12763 (printed 10/18/2005) (2 pages)	

EXAMINER: /Bruce Hissong/	DATE CONSIDERED: 12/14/2007
·	

EXAMINER: Initial if reference considered, whether or noticitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. nelude copy of this form with next communication to Applicant.

'a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier iling date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, re included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are rovided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is elied upon for an earlier filing date under 35 U.S.C. §120.]